Pharmaceuticals

In-Depth Biologics CDMO Market Report: Business Trends, Growth Factors, and Forecast to 2029

September 1, 2025 by Marketing Posting

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only._x000D_

_x000D_

#What Are the Latest Market Insights for the Biologics CDMO Industry?#_x000D_

In recent years, the market size for pulmonary or respiratory drug delivery has witnessed a substantial increase. It is projected to escalate from $69.83 billion in 2024 to $75.67 billion in 2025, with a compound annual growth rate (CAGR) of 8.4%. This surge during the historic period is due to factors such as the growing prevalence of asthma, increased acceptance of advanced inhalation devices, global expansion in healthcare spending, heightened awareness regarding respiratory diseases, and the escalating occurrence of allergic conditions._x000D_

_x000D_

In the coming years, considerable growth is anticipated in the market size for pulmonary or respiratory drug delivery. The market is projected to reach “$105.32 billion in 2029, expanding at a compound annual growth rate (CAGR) of 8.6%.” The forecasted expansion can be linked to factors such as increased interest in personalized medicine, rising chronic respiratory disease rates, growing focus on telemedicine, a surge in healthcare infrastructure investments, and e-commerce growth in the pharmaceutical sector. Key trends anticipated during the forecast period include progress in particle engineering, the emergence of sophisticated nebulizers, liposomal formulation development, advances in computational fluid dynamics, and creation of intelligent inhalers._x000D_

_x000D_

#Download The Free Sample Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=20939&type=smp_x000D_

_x000D_

#What Forces Are Driving The Growth Of The Biologics CDMO Industry?#_x000D_

The biologic CDMO market is anticipated to grow due to the increasing demand for cell and genetic therapy. These innovative medical strategies use living cells or genetic material to address disease causes at the cellular or genetic level. They provide potential remedies for conditions otherwise difficult to treat or cure with conventional medications. The rising demand for these therapies is attributed to their groundbreaking approach in disease treatment, tackling underlying genetic or cellular causes. Biologic CDMOs offer expertise in dealing with living cells, viral vectors, and genetic material. They promote safe and effective production of cell and gene therapies and assist biopharmaceutical companies in meeting regulatory standards and technical obstacles, hence promoting the transition from research to clinical application. For example, The American Society of Gene & Cell Therapy (ASGCT), a top professional membership organization based in the U.S., reported in January 2023 that the gene, cell, and RNA therapy pipeline experienced a 7% growth in 2022, reaching a total of 3,726 therapies under development. Among these, 55% are gene therapies, 22% are non-genetically modified cell therapies, and 23% are RNA therapies. Thus, the rising demand for cell and genetic therapy is fueling the growth of the biologic CDMO market._x000D_

_x000D_

The pulmonary or respiratory drug delivery market covered in this report is segmented – _x000D_

_x000D_

1) By Product: Formulation Type, Device Type_x000D_

2) By Canister Type: Plain Canister, Coated Canister_x000D_

3) By Application: Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis, Other Applications_x000D_

4) By End-User: Hospitals, Clinics, Home Care Settings_x000D_

_x000D_

Subsegments:_x000D_

1) By Formulation Type: Dry Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs), Nebulizers, Liquid Aerosols, Nasal Sprays _x000D_

2) By Device Type: Inhalers (Manual and Digital), Nebulizers (Compressor, Ultrasonic, Mesh), Breath-Activated Devices, Spacer Devices, Nasal Drug Delivery Devices _x000D_

_x000D_

#What Notable Trends Are Shaping The Direction Of The Biologics CDMO Market?#_x000D_

Technological advancements in complex drug delivery systems are the main focus of leading companies in the pulmonary or respiratory drug delivery market as these improvements increase the effectiveness of treatments and patient adherence. These high-tech systems heighten the precise delivery and regulated release of therapeutic substances, which in turn boost drug effectiveness and patient health. An example of this is when Viatris Inc., a US firm that produces generic and branded medicines, and Kindeva Drug Delivery L.P., an American company that specializes in drug delivery, introduced Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol in July 2023. This inhalation aerosol, which has been approved by the US government agency, the Food and Drug Administration, is the first generic version of AstraZeneca’s Symbicort, and is a metered-dose inhaler combining budesonide and formoterol. It’s designed for treating asthma and chronic obstructive pulmonary disease and comes in two strengths: 80 micrograms and 160 micrograms, each containing 4.5 micrograms of formoterol._x000D_

_x000D_

#Who Are The Primary Players Operating Across The Global Biologics CDMO Market?#_x000D_

Major companies operating in the pulmonary or respiratory drug delivery market are Merck & Co. Inc., Novartis AG, Thermo Fisher Scientific Inc., AstraZeneca plc, Abbott Laboratories, 3M Company, Koninklijke Philips N.V., GlaxoSmithKline, Omron Corporation, Teva Pharmaceutical Industries Ltd., Aptar Pharma, Sumitomo Pharma America Inc., Chiesi Farmaceutici S.p.A., Cipla Inc., Boehringer Ingelheim GmbH, Kindeva Drug Delivery Limited, Nemera Group, Hovione, H And T Presspart Group, Vectura Group plc _x000D_

_x000D_

https://www.thebusinessresearchcompany.com/report/pulmonary-or-respiratory-drug-delivery-global-market-report_x000D_

_x000D_

#Which Region Offers The Most Growth Potential For The Biologics CDMO Market Through 2029?#_x000D_

North America was the largest region in the pulmonary or respiratory drug delivery market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary or respiratory drug delivery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Request For A Customized Report:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=20939&type=smp_x000D_

_x000D_

#About The Business Research Company:#_x000D_

_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 7882 955267 & +91 8897263534_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_